Gilead Sciences Inc (GILD)
Gilead Sciences Inc. is a biopharmaceutical company specializing in the development and commercialization of antiviral medicines. Founded in 1987, it is known for its innovative treatments for HIV/AIDS, hepatitis B and C, and other viral infections. Gilead has also expanded into oncology and inflammatory diseases, making significant contributions to advancing global healthcare through its research and development efforts.
Dividend History
Investors can expect a dividend payout of $0.79 per share, scheduled to be distributed in 39 days on December 30, 2025
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 30, 2025 | $0.79 | 2025-12-15 | 2025-12-15 |
| September 29, 2025 | $0.79 | 2025-09-15 | 2025-09-15 |
| June 27, 2025 | $0.79 | 2025-06-13 | 2025-06-13 |
| March 28, 2025 | $0.79 | 2025-03-14 | 2025-03-14 |
| December 30, 2024 | $0.77 | 2024-12-13 | 2024-12-13 |
Dividends Summary
- Gilead Sciences Inc has issued 43 dividend payments over the past 10 years
- The most recent dividend was paid 53 days ago, on September 29, 2025
- The highest dividend payed out to investors during this period was $0.79 per share
- The average dividend paid during this period was $0.64 per share.
Company News
Gilead Sciences reported positive results from a Phase 3 clinical trial for a single-tablet HIV treatment combining bictegravir and lenacapavir, demonstrating non-inferiority to existing multi-tablet regimens with no significant safety concerns.
Nurix Therapeutics will present updated clinical data on bexobrutideg, a novel BTK degrader, at the ASH Annual Meeting, showcasing results in chronic lymphocytic leukemia and Waldenström macroglobulinemia treatments.
The biotech sector shows potential for significant growth by year-end, driven by anticipated Federal Reserve rate cuts and improving market conditions that could benefit rate-sensitive biotech stocks.
MacroGenics reported Q2 2025 financial results with revenue of $22.2 million, missing analyst expectations. The company is focusing on its research-stage pipeline and strategic partnerships while managing costs after exiting its previous marketed product.
Gilead Sciences (GILD) closed the most recent trading day at $69.61, moving -1.58% from the previous trading session.
